The Journal of Emergency Medicine
Volume 24, Issue 1 , Pages 45-54 , January 2003

Utility of platelet adp receptor antagonism in the emergency department: a review

  • Charles V Pollack Jr, MA, MD

      Affiliations

    • Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
    • Corresponding Author InformationReprint Address: Charles V. Pollack, Jr., MA, MD, FAAEM, FACEP, Emergency Medicine, Pennsylvania Hospital, 800 Spruce Street, Philadelphia, PA 19107, USA

Received 13 December 2001 ,Revised 14 June 2002 ,Accepted 26 June 2002.

References 

  1. Braunwald E, Antman EM, Beasley JW, et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)). J Am Coll Cardiol. 2000;36:970–1062 (Updated on March 15, 2002, at http://www.americanheart.org and http://www.acc.org)
  2. Ryan TJ, Antman EM, Brooks NH, et al.  1999 Update. ACC/AHA guidelines for the management of patients with acute myocardial infarction (executive summary and recommendations). Circulation. 1999;100:1016–1030
  3. Spinler S, Cheng J. Antithrombotic therapy after intracoronary stenting. Pharmacotherapy. 1997;17:74–90
  4. Elixhauser A, Yu K, Steiner C, Bierman AS. The top ten conditions for which patients are admitted to the hospital. Hospitalization in the United States: HCUP fact book no. 1. Rockville, MD: Agency for Healthcare Research and Quality; 2000
  5. Yusuf S, Flather M, Pogue J, et al.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet. 1998;352:507–514
  6. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901–2906
  7. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol. 2000;23(Suppl. VI):VI18–22
  8. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In:  Fozzard HA,  Jennings RB,  Haber E,  Katz AM editor. The heart and cardiovascular system. 2nd ed. New York: Raven Press; 1991;p. 219–233
  9. Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol. 2000;23(Suppl. VI):VI3–7
  10. Califf RM, Simoons ML. Use of glycoprotein IIb/IIIa inhibitors in coronary syndromes (state of the art). Am Heart J. 1998;135:S31–55
  11. Schafer AI. Coagulation cascade (an overview). In:  Loscalzo J,  Schafer AI editor. Thrombosis and hemorrhage. Boston: Blackwell Scientific Publications; 1994;p. 3–12
  12. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med. 1996;156:1382–1394
  13. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218
  14. Cairns JA, Theroux P, Lewis HD, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest. 2001;119(Suppl. 1):228S–252S
  15. Smith SC, Dove JT, Jacobs AK, et al.  ACC/AHA guidelines for percutaneous coronary intervention (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty)). J Am Coll Cardiol. 2001;37:2239i–2241xvi
  16. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119(Suppl. 1):300S–320S
  17. Goldstein LB, Adama R, Becker K, et al.  Primary prevention of ischemic stroke (a statement for healthcare professionals from the Stroke Council of the American Heart Association). Circulation. 2001;103:163–182
  18. Alexander JH, Harrington RA, Tuttle RH. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol. 1999;83:1147–1151
  19. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function (implications for the use of ASA clinically). Can J Cardiol. 1995;11:221–227
  20. Helgason CM, Bolin KM, Hoff JA. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331–2336
  21. Grotemeyer K-H, Scharafinski H-W, Husstedt I-W. Two-year follow-up of aspirin responder and aspirin nonresponder (a pilot study including 180 post-stroke patients). Thromb Res. 1993;71:397–403
  22. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553–1559
  23. Schror K. The basic pharmacology of ticlodipine and clopidogrel. Platelets. 1993;4:252–261
  24. Humbert M, Nurden P, Bihour C, et al.  Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532–1543
  25. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlodipine and clopidogrel. Ann Intern Med. 1998;129:394–405
  26. Van de Graaff E, Steinhubl SR. Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med. 2000;32:561–571
  27. Savcic M, Hauert J, Bachmann F, et al.  Clopidogrel loading dose regimens (kinetic profile of pharmacodynamic response in healthy subjects). Semin Thromb Hemost. 1999;25(Suppl. 2):15–19
  28. Herbert J-M, Frechel D, Vallee E, et al.  Clopidogrel, a novel antithrombotic agent. Cardiovasc Drug Rev. 1993;11:180–198
  29. Cadroy Y, Bossavy J-P, Thalamas C, Sagnard L, Sakariassen KS, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101:2823–2828
  30. Helft G, Osende JI, Worthley SG, et al.  Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316–2321
  31. Gent M, Blakeley JA, Easton JD, et al.  The Canadian American Ticlodipine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215–1220
  32. Gill S, Majumdar S, Brown NE, Armstrong PW. Ticlodipine-associated pancytopenia (implications of an acetylsalicylate acid alternative). Can J Cardiol. 1997;13:909–913
  33. Package insert, Ticlopidine hydrochloride, Roche Laboratories
  34. Bennet C, Weinberg P, Rozenberg-Ben-Dror K, Yarnold P, Kwaan H, Green D. Thrombotic thrombocytopenic purpura associated with ticlodipine (a review of 60 cases). Ann Intern Med. 1998;128:541–544
  35. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlodipine. Lancet. 1991;337:774–776
  36. Darius H, Rupprecht H-J, Kress P, et al.  Accelerated inhibition of platelet activity by clopidogrel loading dose in patients following coronary stent implantation. Eur Heart J. 1999;20:252; (Abstr. Suppl.)
  37. Harker LA, Marzec UM, Kelly AB, et al.  Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation. 1998;98:2461–2469
  38. Herbert J-M, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80:512–518
  39. Makkar RR, Eigler NL, Kaul S, et al.  Effects of clopidogrel, aspirin, and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J. 1998;19:1538–1546
  40. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  41. Schomig A, Neumann F-J, Kastrati A, et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084–1089
  42. CLASSICS Investigators Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlodipine in combination with aspirin after coronary stenting (the clopidogrel aspirin stent international cooperative study (CLASSICS)). Circulation. 2000;102:624–629
  43. Cutlip DE, Leon MB, Ho KK, et al.  Acute and nine-month clinical outcomes after “suboptimal” coronary stenting (results from the STent Anti-thrombotic Registry Study (STARS) registry). J Am Coll Cardiol. 1999;34:698–706
  44. Bertrand ME, Legrand V, Boland J, et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597–1603
  45. Urban P, Macaya C, Rupprecht H-J, et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126–2132
  46. Moore SA, Steinhubl SR. Clopidogrel and coronary stenting (what is the next question?). J Thromb Thrombolysis. 2000;10:121–126
  47. Moliterno DJ, Topol EJ. A direct comparison of tirofiban and Abciximab during percutaneous coronary revascularization and stent placement (rationale and design of the TARGET study). Am Heart J. 2000;140:722–726
  48. TARGET International Steering Committee, 6-month results posted on http://www.theheart.org (accessed December 20, 2002).
  49. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme (rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease). Eur Heart J. 2000;21:2033–2041
  50. CAPRIE Steering Committee . A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  51. Gent M. Benefit of clopidogrel in patients with coronary disease (abstract). Circulation. 1997;96:I647
  52. Balsano F, Rizzon P, Violi F, et al.  Antiplatelet treatment with ticlodipine in unstable angina (a controlled multicenter clinical trial). Circulation. 1990;82:17–26
  53. PURSUIT Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443
  54. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. [published erratum appears in N Engl J Med 1998 Aug 6;339:415] N Engl J Med. 1998;338:1488–1497
  55. Hall P, Nakamura S, Mailleo L, et al.  A randomized comparison of combined ticlodipine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215–222
  56. Albiero R, Hall P, Itoh A, et al.  Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlodipine and aspirin therapy. Circulation. 1997;95:1145–1156
  57. Hass WK, Easton JD, Adams HP, et al.  A randomized trial comparing ticlodipine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–507
  58. Gent M, Blakely JA, Easton JD, et al.  The Canadian American ticlodipine study (CATS) in thromboembolic stroke. Lancet. 1989;2:1215–1220
  59. Bhatt DL, Hirsch AT, Ringleb PA, Haden W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 2000;140:67–73
  60. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus. J Am Coll Cardiol. 2000;35(Suppl. A):409
  61. Bhatt DL, Foody JM, Hirsch AT, Reingleb PA, Hacke W, Topol EJ. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol. 2000;35(Suppl. A):326
  62. Bhatt DL, Hirsch AT, Chew DP, Ringleb P, Hacke W, Topol EJ. Marked superiority of clopidogrel versus aspirin in patients with a history of previous cardiac surgery. J Am Coll Cardiol. 2000;35(Suppl. A):383
  63. Bhatt DL, Kapadia SR, Yadav JS, Topol EJ. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Cerebrovasc Dis. 2000;10(Suppl. 5):34–40
  64. Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86

☆ Pharmacology in Emergency Medicine is coordinated by Richard F. Clark, MD, of the University of California San Diego Medical Center, San Diego, California

PII: S0736-4679(02)00680-7

doi: 10.1016/S0736-4679(02)00680-7

The Journal of Emergency Medicine
Volume 24, Issue 1 , Pages 45-54 , January 2003

Article Tools

* Image Usage & Resolution